MERCATOR MEDSYSTEMS NAMES ANTHONY REMINGTON CHIEF COMMERCIAL OFFICER

SAN LEANDRO, CA – (August 15, 2013) – Mercator Medsystems, a venture-backed, privately held medical technology company delivering customizable solutions for intractable problems associated with significant diseases, today announced the appointment of Anthony B. Remington as Chief Commercial Officer, effective immediately.  In this role, Mr. Remington will be responsible for developing and integrating Mercator's strategic marketing, sales, product development and customer service goals to drive business growth and market share.

"We are delighted to welcome Tony to Mercator's executive team," said Chief Executive Officer Thomas M. Loarie. "He possesses a unique combination of experience and success in building winning commercial strategies and attracting world class sales and sales support professionals.  Tony has a proven track record in meeting or exceeding strategic commercial objectives for some of the world's leading medical device companies," he added, "and specializes in developing and executing distribution strategies for early stage device companies, as well."

Mr. Remington has served as a strategic sales advisor for Mercator Medsystems since January, 2013. Prior to this, he held executive positions in sales and commercial operations for Estech Corporation (2009 – 2012) and Ekos Corporation 2006-2009).  He brings more than sixteen years of diverse medical specialty experience with increasing sales management responsibility for multi-national corporations (Medtronic, Guidant Corporation, and C. R. Bard, Inc.), LeMaitre Vascular (LMAT), and two venture-backed start-up companies.

Mr. Remington earned a B.S. degree in Marketing from Bentley College and an M.B.A. from the Carroll School of Management at Boston College.

~  ~   ~ 

San Leandro, CA-based Mercator MedSystems, Inc. (www.mercatormed.com) is a venture-backed, privately held medical technology company delivering innovative, customizable, treatment solutions for intractable problems associated with some of the world's most significant diseases.  Spun out of The University of California, Berkeley, the company develops catheter-guided micro-infusion systems for targeted delivery of drugs and biologics deep inside the body to treat the root cause of a growing portfolio of medical conditions, including cardiovascular disease, cancer, hypertension and heart disease.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.